Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Heightens Focus On Cannabis With Hiring Of Norman Birenbaum As Public Health Advisor

Executive Summary

Industry reps are glad that Birenbaum, who was the chief cannabis policy advisor to the governors of New York and Rhode Island, was given a prominent role at FDA that could spur regulatory action.

You may also be interested in...



Senate Cannabis Bill Could Torch US Hemp Market By Slashing THC Limit Below Farm Bill Level

Hemp Roundtable says Cannabis Administration and Opportunity Act’s limit of 0.001% THC per 100 g by dry weight for ingredients derived from cannabis to qualify as hemp “would impose a devastating setback to a thriving industry, and further limit opportunities for already struggling hemp farmers.”

Safety Concerns Are US FDA's Answer To Question On Regulatory Pathway For Hemp’s Lawful Use

While not asking Science Board for recommendations on allowing lawful use of hemp in non-drug products, agency officials gave clear indication of current position on the question.

US Hemp Product Industry ‘Dying On Vine’ Without Lawful Use Legislation Or Enforcement Guidance

FDA’s tolerance of sales of hemp-containing supplements isn’t the assurance  industry needs for investing in development of ingredients and products which have been shown to provide various health benefits.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS147073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel